首页> 美国卫生研究院文献>other >Breaking the Spell: Combating Multidrug Resistant ‘Superbugs’
【2h】

Breaking the Spell: Combating Multidrug Resistant ‘Superbugs’

机译:打破魔咒:对抗耐多药的超级细菌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Multidrug-resistant (MDR) bacteria have become a severe threat to community wellbeing. Conventional antibiotics are getting progressively more ineffective as a consequence of resistance, making it imperative to realize improved antimicrobial options. In this review we emphasized the microorganisms primarily reported of being resistance, referred as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacteriaceae) accentuating their capacity to “escape” from routine antimicrobial regimes. The upcoming antimicrobial agents showing great potential and can serve as alternative therapeutic options are discussed. We also provided succinct overview of two evolving technologies; specifically network pharmacology and functional genomics profiling. Furthermore, In vivo imaging techniques can provide novel targets and a real time tool for potential lead molecule assessment. The employment of such approaches at prelude of a drug development process, will enables more informed decisions on candidate drug selection and will maximize or predict therapeutic potential before clinical testing.
机译:耐多药(MDR)细菌已成为对社区福祉的严重威胁。由于抗药性,常规抗生素正变得越来越无效,这使得必须实现改善的抗微生物选择。在这篇综述中,我们强调了主要报道为抗药性的微生物,称为ESKAPE病原体(粪肠球菌,金黄色葡萄球菌,肺炎克雷伯菌,鲍曼不动杆菌,铜绿假单胞菌和肠杆菌科),强调了它们从常规抗微生物剂中“逃脱”的能力。讨论了显示出巨大潜力并可以用作替代治疗选择的抗菌药物。我们还简要概述了两种不断发展的技术。特别是网络药理学和功能基因组学分析。此外,体内成像技术可以为潜在的铅分子评估提供新颖的靶标和实时工具。在药物开发过程的前奏中采用这种方法,将使候选药物的选择更加明智,并在临床测试之前最大化或预测治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号